Market Overview

Brinson Patrick Reiterates Market Outperform on Novavax on Strong Finish to 2012


In a report published Monday, Brinson Patrick reiterated its Market Outperform rating and $3.00 price target on Novavax (NASDAQ: NVAX).

Brinson Patrick noted, “Novavax Inc. (NVAX) has three vaccine candidates in active evaluation in four different therapeutic indications and a fourth candidate expected to enter clinical evaluation in 2013. We look for topline data from the ongoing respiratory syncytial virus (RSV) Phase II and I studies in April and 2H13, respectively, CPLB's advancement of a rabies vaccine using Novavax technology into a clinical trial, as well as updates on the company's vaccine programs in foot-and-mouth disease, and malaria, to be drivers of the stock in 2013.”

Novavax closed on Friday at $2.05.

Latest Ratings for NVAX

Nov 2020HC Wainwright & Co.MaintainsBuy
Aug 2020HC Wainwright & Co.MaintainsBuy
Aug 2020B. Riley FBRMaintainsBuy

View More Analyst Ratings for NVAX
View the Latest Analyst Ratings


Related Articles (NVAX)

View Comments and Join the Discussion!

Posted-In: Brinson PatrickAnalyst Color Reiteration Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at